Figure 17.

a) Synthetic aluminum‐integrated antigen–MOF (ZANPs) for effective targeting of lymph node (LN)‐resident DCs and efficient induction of immunotherapy. Reproduced with permission.^{[ 63 ]} Copyright 2019, Elsevier. b) Schematic illustration of Al–BSA–Ce6‐based immunotherapy. Reproduced with permission.^{[ 222 ]} Copyright 2020, Elsevier. c) The therapeutic process and synthesis routine of ZnS@BSA nanoclusters. Reproduced with permission.^{[ 223 ]} Copyright 2021, Wiley‐VCH. d) Schematic illustration of NVs^cp formation and the mechanisms of NVs^cp‐induced cancer immunotherapy. Reproduced with permission.^{[ 225 ]} Copyright 2021, Elsevier.